PEB Completes Oversubscribed NZ$36.1m Capital Raise

3 June 2026
PACIFIC EDGE COMPLETES NZ$36.1 MILLION CAPITAL RAISING;
RETAIL OFFER CLOSES SIGNIFICANTLY OVERSUBSCRIBED
DUNEDIN, New Zealand – On 13 May 2026, cancer diagnostics company Pacific Edge
(NZX/ASX: PEB) confirmed a NZ$31.4 million capital raising at NZ$0.17 per share, comprising
a NZ$25.4 million placement (Placement) and a NZ$6 million retail offer (with the ability to
accept over-subscriptions at PEB’s discretion) (Retail Offer).
The Retail Offer closed on 28 May 2026, with total applications for NZ$46.0 million of new
ordinary shares. In recognition of strong Retail Offer support, the Directors have resolved to
accept NZ$4.7 million of oversubscriptions to raise NZ$10.7 million under the Retail Offer. This
has resulted in the vast majority of applicants under the Retail Offer receiving an allocation
meaning they at least maintain their relative pre-capital raising shareholding (or if they applied
for a lesser amount, their full application).
The proceeds from the Retail Offer, combined with the associated NZ$25.4 million Placement
that preceded it, brings the new equity raised to NZ$36.1 million in aggregate.
The Retail Offer was open to “Eligible Shareholders”, who are all persons recorded on Pacific
Edge’s share register at 7:00pm NZST on Friday, 8 May 2026 as being a holder of Pacific Edge
shares and having an address in New Zealand.
Of the NZ$10.7 million raised under the Retail Offer, NZ$10.2 million will be issued under the
share purchase plan rules (NZX Listing Rule 4.3.1(c)) and NZ$0.5 million under Pacific Edge’s
placement capacity (NZX Listing Rule 4.5.1). The Retail Offer was scaled in accordance with
the terms contained in the Retail Offer Document, dated 14 May 2026. Scaling of all
applications under the Retail Offer was undertaken with reference to the number of shares held
by Eligible Shareholders accepting the Retail Offer at 7:00pm NZST on the record date of 8
May 2026.
Under the Retail Offer, 62,703,746 new shares will be issued at NZ$0.17 per share. All shares
issued as part of the Retail Offer are expected to be allotted to participants on 4 June 2026
and will rank equally with all ordinary shares on issue on that date. Trading of new shares
issued under the Retail Offer is expected to commence on NZX on 4 June 2026.
Confirmation of the number of shares issued to participating shareholders under the Retail
Offer will be sent on or around 4 June 2026.
The refund of any surplus application amounts will occur within five business days following
settlement in accordance with the terms of the Retail Offer.
Pacific Edge is grateful for the ongoing support of Pacific Edge shareholders.
Chairman Simon Flood said: "Pacific Edge is in a strong strategic position supported by our
successful capital raising of NZ$36.1 million. The long-term opportunity ahead for Cxbladder
has been reinforced by the quality of the company's clinical evidence, the strength of support

2

expressed at the Novitas-convened Contractor Advisory Committee in February 2026, the
growing recognition from commercial payers, the early wins in APAC and now the draft LCD.”
“We are immensely grateful for the support of our shareholders, with over 93% of the capital
raised coming from existing shareholders. We are looking forward to seeing this support
rewarded with a return to growth and delivery on the significant potential we see for Pacific
Edge.”

Ends.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer
For more information:
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: + 64 22 032 1263
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with hematuria and those being monitored for recurrent
disease. The tests help improve the overall patient experience, while prioritizing time and
clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered

3

more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.